BIOMIMESYS® 3D technology is a natural HA-based scaffold to better mimic the tissue microenvironment and provide more predictive tools for drug development. The BIOMIMESYS® products are formed by crosslinking reaction of hydrosoluble modified hyaluronic acid and others matrix components with ADH (adipic acid dihydrazide), to mimic the extracellular matrix (ECM). Depending on the organ, ECM components vary and are present in different proportions, allowing a more or less dense and compact cellular environment. BIOMIMESYS® 3D technology allows us to reproduce the cell microenvironment of each organ.
Click here to get more information!
To ensure personalised treatment for familial hypercholesterolemia
To develop relevant 3D models of different tumors, in order to better assess the efficiency of anticancer therapies.
A holistic approach to address brain delivery
Face to the high failure of drug candidate in clinical trial, in particular involving the brain, we goal to develop more relevant and more predictive in vitro models for preclinical assessment, in the aim to early select molecules of interest, in term of efficacy and safety.
To design and industrialize new pharmacological in vitro assays for the screening of compounds/biopharmaceuticals in 3D
To develop the technological platform to produce lab-grown meats. The project is funded by EUREKA and the national funding agencies associated with the Eurostars program.
To develop a universal “plug-and-play” liver-on-chip platform mimicking the major events occurring in the liver sinusoid in order to predict the hepatoxicity of drugs.
To explore the use of AI technologies to improve different steps of 3D biological picture exploitation
In HCS Pharma we strongly believe that 3D cell culture is the right way to improve drug dicovery processes. Moreover, we know that our 3D HydroscaffoldTM matrix BIOMIMESYS® could be useful for bioproduction. We will be happy Read more…
This is the end of Rania‘s 6-month internship in HCS Pharma about a new liver biochip system. After a first publication “Development of Liver-on-Chip Integrating a Hydroscaffold Mimicking the Liver’s Extracellular Matrix” in collaboration with Read more…
BIOMIMESYS® has taken place in the panel of the future medicine on the 27th of September. The next step has arrived, and Nathalie Maubon CEO of HCS Pharma has taken BIOMIMESYS® all the way to Read more…
The great meeting for the cosmetic field “Cosmetic 360” is back again ! Oceane GUYOT our project manager in dermocosmetology and Rita HIEN our business developper will be at this event on the 18th/19th and Read more…
HCS Pharma is speeding up its expansion into Asia ! Our CEO/CSO Mme. Nathalie MAUBON will again be in Asia and speak for the first time in China ! Mme. MAUBON will deliver a speech Read more…
In HCS Pharma we strongly believe that 3D cell culture is the right way to improve drug dicovery processes. Moreover, we know that our 3D hydroscaffold matrix BIOMIMESYS® could be useful for bioproduction and then for cell Read more…
Find out more about BIOMIMESYS® and its wide range of applications (oncology, neurosciences, metabolism, adipocyte research) in this informative article. A comprehensive article describing the benefits of our products and the importance of results in Read more…
Skin redness is a sign of cutaneous inflammation which can lead to major skin disorders. When the skin is exposed to allergens, irritants, pathogens, or UV rays, cells produce a variety of inflammatory cytokines which bind to specific Read more…
Positive thinking = positive living ! Welcome back to work ! HCS Pharma wishes you a safe return to work and stay available to advice you about how our breaktrough 3D technologies BIOMIMESYS® declined for Read more…
Thomas Meynard is a PhD student in OncoLille Laboratory (Canther Lab, Mucine Team), under the supervision of Dr. Isabelle Van Seuningen and Dr. Vincent Senez. His PhD work is focused on the development of microfluidic Read more…
In Asia for a business trip, Nathalie Maubon, PhD, CEO & CSO of HCS Pharma, participated in a symposium during BioAsia event on late July, together with LumiSTAR Biotechnology (Taïwan) and Molecular Devices (USA). On Read more…
The Perseid meteor shower which is taking place on the 14th of July and will finish on the 1st September will reach its high point between the 10 and the 14th of August. Debris from Read more…
Rehovot (Israel) London (UK) and Lille (France) Vidac Pharma is a clinical stage biopharmaceutical company dedicated to discovering and developing First-in-class medicines to help people suffering from a range of oncologic and dermatologic diseases. Vidac Read more…
We are happy to share that Nathalie Maubon, PhD, our CEO/CSO is currently attending BioAsia Taiwan, organized in Taipei. The event aims at building on the success of recent years’ gatherings to bring together biotechnology Read more…
Organisms store lipids when they consume more energy than they can use immediately. In mammals, adipose tissue, in addition to its role as an endocrine organ, is specialized in fat storage. Adipose tissue is mainly Read more…
Julien Cicero, with whom we are collaborating about the study of breast cancer metastasis mechanisms, was proud to present his PhD work during the last EACR conference. It was held in Torino (Italy) last month, Read more…
Chez HCS Pharma, nous sommes ravis de partager avec vous les avancées significatives que nous avons réalisées dans nos projets de recherche et développement. Avant de commencer, nous tenons à remercier “La Gazette du Laboratoire” Read more…
HCS Pharma – Siège de Lille
Biocentre Fleming Bat A
250 rue Salvador Allende
59120 LOOS
See on map
+33 769 999 137
Only for customers please, if you have another interest use the form contact.